At a glance
- Originator Showa Denko
- Developer Nonindustrial source; Showa Denko
- Class Antithrombotics; Aromatic amino acids; Essential amino acids; Small molecules
- Mechanism of Action Kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 14 Nov 2000 Discontinued-Preclinical for Thrombosis in Japan (Unknown route)
- 23 Sep 1998 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 04 Jul 1996 New profile